🇨🇭·Jan 1, 1970Industry
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Publisher
N
Novartis News
Switzerland
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Novartis News
- Region
- Switzerland
- Scope
- Industry
- Published
- January 1, 1970
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on novartis.com
Leave the platform to read the original full article on the publisher site.
Source: Novartis News
Scope: Industry
Related coverage
More related coverage
GSK News/6h ago
GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)
Natco Pharma/15h ago
natco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26
Natco Pharma/15h ago
natco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26
Natco Pharma/15h ago